buysid read top note
april miss
april data show earn preview boston
day highlight read report top most-read insid
tabl link select rank-ord note jefferi biotech
team addit highlight report team uniqu
insight differenti view revisit
industri preview/cal bounc expect ok apr
new car-t off-the-shelf co ex-kit leader play futur apr
celg management chang surpris investor discuss apr
detail avx acquisit one multipl parti interest apr
industri avx help group other gene apr
industri read yee leav sentiment investor discuss apr
industri top biotech note read buysid march apr
industri video tough matter come apr
industri easl dinner takeaway liver pari apr
day one event focus thought cardiologist neurologist
hereditari ttr amyloidosi jefferi complement
summit third annual summit includ multipl compani present two
expert panel hematolog neurolog
amin biren key report industri present result
proprietari survey tardiv dyskinesia indic ingrezza could see rev
modestli beat consensu think beat driven expans
treat patient q/q due better prescrib educ incomplet convers
mg bid less profit mg qd preview expect poc
data radar asset congenit adren hyperplasia deep
dive indic there market opportun orphan diseas expect
upsid minim downsid posit signal reduct hormon
biomark host annual io cell therapi summit
allogen new biotech launch off-the-shelf car-t technolog gave
first investor corpor present ceo david chang twenti compani
present highlight cover compani blcm
matthew andrew key report amrn amrn doc survey
suggest posit reduce-it data could increas vascepa use md/shtg
patient neg data could lead lower use doc dont plan decreas
use share see favor upsid downsid data
aua abstract interim data olympu studi
mitogel show impress cr rate enrol well good earli
cr durabl concern full data hold continu see
high likelihood approv mitogel cr hurdl like
top-line result pfe stabil tafamidi seem come surpris attr space
howev believ devil could ph iii data detail impli
boston day summar thought nv acquisit
avx bring attent also use construct lead vivo
gene tx program addit score big win rmat design mp
initi coverag ecyt buy -- like name part
recent acquir de-risk ph iii asset prostat cancer well asco
data soon ecyt also develop differenti univers car-t program support
co-founder juno
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
exhibit list select note publish jefferi biotech team sort hit continu next page
preview/cal bounc expect ok numbers/guid
new car-t off-the-shelf co ex-kit leader play futur strategi
management chang surpris investor discuss
detail avx acquisit one multipl parti interest
 avx help group other gene therapi comp sheet
read yee leav sentiment investor discuss top event come
top biotech note read buysid march miss
video tough matter come
easl dinner takeaway liver pari
management meet could surpris upsid scenario phase studi
celg nv suggest drg code might come sooner car-t
meet management three new posit data point nash easl buy
think ep week buy
new ozanimod rtf question continu linger find may
could go level minor pipelin valu
asco data first look titl hit
valu vs growth trade fundament thing matter come
headlin predict bounc back like other situat
investor question expect upcom phase data buy
w/ management ahead upcom data year buy
video think come key ep next week
phase gene therapi studi track long-term data show durabl
recent pullback like due anyth new competit etc buy
ctlr-alt-del reboot early-pipelin take time move hold
ipf imag fibrosi data updat at continu look
expect ok quarter focu long-term hold
conf-cal insist plenti capac premium frothi
confer call takeaway minut second
increment start year in-lin w/our thesi buy
conf call point min sec
in-line/light partial impact inventori chang thesi hold
new suggest bear case competit like go away time
stabil improv knockdown benefit beat tafamidi buy weak
asgct titl post
takeaway boston day hereditari ttr amyloidosi
takeaway jefferi boston day attr gene-edit
takeaway boston day hereditari ttr amyloidosi
reduce-it remain track transform mace data
vote tri reduc cf drug price new york seem noisi best
new symdeko overal good anoth phase tripl pill start
page
pleas see import disclosur inform page report
exhibit list select note publish jefferi biotech team sort hit
initi buy potenti game prostat cancer w/ car-t innov
takeaway jefferi boston day amrn
half way olympu cr rate mitogel lg utuc
one step closer end nda odyssey fda label negoti underway
updat pozi nsclc data continu look better hope mdacc/sppi
pozi shine exon nsclc potenti
w/ management -- new ceo w/ catalyst rich under-valued portfolio
aacr clear broad activ competitor loxo data
biotech short interest market cap
brazilian court unanim decid allow gener product soliri
failur progress gmg argx rarx
part bigger pictur buy stock prior storm could pay
mdacc publish pre-clin clinic pozi exon nsclc data
takeaway boston day peanut allergi dbvt
part catalyst believ storm data posit
under-appreci phase asset unmet need initi buy
w/ management -- connect dot outlin underappreci opportun
sell-off overdon miss igan bear fosta approv itp
itch ad creat equal tradipit serlopit
rmat design major win de-risk event mp iiia
takeaway boston day huntington diseas hd
human factor test complet readi dsuvia nda re-submiss
increment better ublituximab rm data meet
biotech short interest market cap
fda approv tavaliss chronic itp anticip
biomark data yet-to-b translat clinic benefit hd
in-lin net loss clinic data catalyst
updat investor meet dova manag
posit chmp opinion dzuveo fda approv dsuvia still tbd
ep larg lower opex/tax second success
page
pleas see import disclosur inform page report
